GlassScriptPhysician profile
Elizabeth M Rocco
NPI 1922174077
$2,918.87
in general payments reported to CMS, 2019-2025
30 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $212 · 2021: $71.45 · 2022: $166 · 2023: $601 · 2024: $922 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.13 | 2023-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.38 | 2020-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $216.69 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $209.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.00 | 2023-2025 | Caplyta |
| Lundbeck LLC | $178.14 | 2022-2024 | Rexulti |
| Celgene Corporation | $140.07 | 2019 | |
| Pfizer INC. | $123.49 | 2024-2025 | |
| Amgen INC. | $122.86 | 2020-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $110.26 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $106.18 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Gilead Sciences, INC. | $103.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.19 | 2020-2024 | Airsupra, Fasenra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $81.84 | 2022-2025 | Rexulti |
| Ardelyx, INC. | $56.66 | 2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.77 | 2023-2025 | |
| Electromed, INC. | $36.75 | 2025 | Smartvest |
| Nestle Healthcare Nutrition INC. | $34.75 | 2021-2022 | |
| Scpharmaceuticals INC. | $34.68 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.92 | 2022-2025 | Xifaxan |
| Almatica Pharma LLC | $28.24 | 2023 | Loreev Xr, Gralise |
| Sumitomo Pharma America, INC. | $25.20 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $22.43 | 2024 | Xtampza |
| Idorsia Pharmaceuticals US INC | $20.55 | 2022 | |
| Daiichi Sankyo INC. | $20.35 | 2022 | |
| Medtronic, INC. | $19.40 | 2023 | Closurefast |
| Baxter Healthcare | $19.35 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $16.19 | 2020 | |
| Redhill Biopharma INC. | $15.35 | 2021 | |
| Amarin Pharma, INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Rocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.